Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, 1540 E. Hospital Drive, CW 7-251B, Ann Arbor, MI 48109, United States.
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, United States.
Crit Rev Oncol Hematol. 2020 Apr;148:102897. doi: 10.1016/j.critrevonc.2020.102897. Epub 2020 Feb 13.
Advanced classical Hodgkin lymphoma (cHL) is a rare lymphoid disease characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells. Each year, cHL accounts for 0.5% of all new cancer diagnoses and about 80% are diagnosed with advanced stage disease. Given the significant improvement in cure rates, the focus of treatment has shifted towards minimization of acute and long-term toxicities. PET-adapted strategies have largely been adopted as standard of care in the United States in an attempt to balance toxicities with adequate lymphoma control. However, the appropriate upfront chemotherapy regimen (ABVD versus eBEACOPP) remains controversial.
高级经典型霍奇金淋巴瘤（cHL）是一种罕见的淋巴细胞疾病，其特征是存在霍奇金和里德-斯特恩伯格（HRS）细胞。每年，cHL 占所有新诊断癌症的 0.5%，约 80%被诊断为晚期疾病。鉴于治愈率的显著提高，治疗的重点已转向尽量减少急性和长期毒性。在美国，PET 适应策略已被广泛采用作为标准治疗方法，试图在充分控制淋巴瘤的同时平衡毒性。然而，合适的初始化疗方案（ABVD 与 eBEACOPP）仍然存在争议。
